Heart rhythm disturbances associated with rupatadine: A case series from the Spanish and Portuguese pharmacovigilance systems

Clinical Pharmacology and Therapeutics

Volumn 85, Issue 5, 2009, Pages 481-484

  Carvajal, A ^a   MacIas D ^a   Salado, I ^a   Sainz M ^a   Ortega, S ^a   Campo, C ^a   Garcia Del Pozo J ^a   Martin Arias L H ^a   Velasco, A ^a   Goncalves S ^b   Pombal, R ^b   Carmona, R ^b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b INFARMED)   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ASTEMIZOLE; AZELASTINE; CETIRIZINE; DESLORATADINE; EBASTINE; FEXOFENADINE; LEVOCETIRIZINE; LORATADINE; MIZOLASTINE; RUPATADINE; TERFENADINE;

ADULT; AGED; ALLERGIC RHINITIS; ALLERGY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ECZEMA; FEMALE; HEART ARRHYTHMIA; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; LONG QT SYNDROME; MALAISE; MALE; NAUSEA; PRIORITY JOURNAL; RHINITIS; SIDE EFFECT; SWEATING; SWELLING; TACHYCARDIA; TORSADE DES POINTES; WEAKNESS; XEROSTOMIA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ARRHYTHMIAS, CARDIAC; CYPROHEPTADINE; DATABASES, FACTUAL; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PORTUGAL; SPAIN;

EID: 67349121245     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.269     Document Type: Article

References (29)

1. Martindale: The Complete Drug Reference Accessed Through MedicinesComplete . Accessed March 2007.
2. Merlos, M. et al. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF). J. Pharmacol. Exp. Ther. 280, 114-121 (1997).
3. Lindquist, M. & Edwards, I.R. Risks of non-sedating antihistamines. Lancet 349, 1322 (1997).
4. de Abajo, F.J. & Rodríguez, L.A. Risk of ventricular arrhythmias associated with nonsedating antihistamine drugs. Br. J. Clin. Pharmacol. 47, 307-313 (1999).
5. Woosley, R.L. Cardiac actions of antihistamines. Annu. Rev. Pharmacol. Toxicol. 36, 233-252 (1996).
6. Monahan, B.P., Ferguson, C.L., Killeavy, E.S., Lloyd, B.K., Troy, J. & Cantilena, L.R. Jr. Torsades de pointes occurring in association with terfenadine use. JAMA 264, 2788-2790 (1990).
7. Handley, D.A., Magnetti, A. & Higgins, A.J. Therapeutic advantages of third generation antihistamines. Expert Opin. Investig. Drugs 7, 1045-1054 (1998).
8. Nombela-Franco, L., Ruiz-Antoran, B., Toquero-Ramos, J. & Silva-Melchor, L. Torsades de pointes associated with rupatadine. Rev. Esp. Cardiol. 61, 328-329 (2008).
9. Keam, S.J. & Plosker, G.L. Rupatadine: a review of its use in management of allergic disorders. Drugs 67, 457-474 (2007).
10. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. ICH Harmonised Tripartite Guideline. Current step 4 version. International Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, 12 May 2005 [online] .
11. Donado, E. et al. Cardiac safety of rupatadine according to the new ICH guideline: a "thorough QT/QTc study". XXV Congress of the European Academy of Allergology and Clinical Immunology, Vienna, Austria, 10-14 June 2006. Abstract 760.
12. Caballero, R., Valenzuela, C., Longobardo, M., Tamargo, J. & Delpón, E. Efects of rupatadine, a new dual antagonist of histamine and platelet-activating factor receptors, on human cardiac Kv1.5 channels. Br. J. Pharmacol. 128, 1071-1081 (1999).
13. García Rafanell, J. Rupatadine fumarate: antiallergic histamine and PAF antagonist. Drugs Future 21, 1032-1036 (1996).
14. Fitzgerald, P.T. & Ackerman, M.J. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm 2 (2 suppl.), S30-S37 (2005).
15. Alvarez-Requejo, A., Carvajal, A., Bégaud, B., Moride, Y., Vega, T. & Arias, L.H. Under-reporting of adverse drug reactions. Estimate based on a spontaneous reporting scheme and a sentinel system. Eur. J. Clin. Pharmacol. 54, 483-488 (1998).
16. Tamargo, J. Drug-induced torsade de pointes: from molecular biology to bedside. Jpn. J. Pharmacol. 83, 1-19 (2000).
17. Liu, H., Zheng, Q. & Farley, J.M. Antimuscarinic actions of antihistamines on the heart. J. Biomed. Sci. 13, 395-401 (2006).
18. Hove-Madsen, L. et al. The proarrhythmic antihistaminic drug terfenadine increases spontaneous calcium release in human atrial myocytes. Eur. J. Pharmacol. 553, 215-221 (2006).
19. Llenas, J., Cardelús, I., Heredia, A., de Mora, F. & Gristwood, R.W. Cardiotoxicity of histamine and the possible role of histamine in the arrhythmogenesis produced by certain antihistamines. Drug Saf. 21 (suppl. 1), 33-38; discussion 81-87 (1999).
20. Heredia, A., Beleta, J. & Llenas, J. Terfenadine and the main metabolite of loratadine release histamine from cardiac mast cells: possible cardiotoxic consequences. Ann. Allergy Asthma Immunol. 78, 142 (1997).
21. Darpö, B. Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace 9 (suppl. 4), iv23-iv36 (2007).
22. World Health Organization. International Monitoring of Adverse Reactions to Drugs: Adverse Reaction Terminology (World Health Organization Collaborating Centre for International Drug Monitoring, Uppsala, Sweden, 1992).
23. Brown, E.G., Wood, L. & Wood, S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 20, 109-117 (1999).
24. Moore, N. et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br. J. Clin. Pharmacol. 44, 513-518 (1997).
25. Evans, S.J. Pharmacovigilance: a science or felding emergencies? Stat. Med. 19, 3199-3209 (2000).
26. Rothman, K.J., Lanes, S. & Sacks, S.T. The reporting odds ratio and its advantages over proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519-523 (2004).
27. Miettinen, O.S. & Wang, J.D. An alternative to the proportionate mortality ratio. Am. J. Epidemiol. 114, 144-148 (1981).
28. Ulm, K. A simple method to calculate the confdence interval of a standardized mortality ratio (SMR). Am. J. Epidemiol. 131, 373-375 (1990).
29. Dobson, A.J., Kuulasmaa, K., Eberle, E. & Scherer, J. Confdence intervals for weighted sums of Poisson parameters. Stat. Med. 10, 457-462 (1991).